Publications by Evita Maria Lindholm
8 publications found
Original articles
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
Microrna, 8 (2), 155-165
DOI 10.2174/2211536608666181206124922, PubMed 30520388
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations
Clin Cancer Res, 20 (2), 404-12
DOI 10.1158/1078-0432.CCR-13-1865, PubMed 24192926
Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
J Magn Reson Imaging, 38 (5), 1043-53
DOI 10.1002/jmri.24079, PubMed 23908122
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
Mol Oncol, 7 (1), 130-42
DOI 10.1016/j.molonc.2012.10.005, PubMed 23142657
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts
Mol Oncol, 6 (4), 418-27
DOI 10.1016/j.molonc.2012.03.006, PubMed 22521242
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts
J Magn Reson Imaging, 35 (5), 1098-107
DOI 10.1002/jmri.23507, PubMed 22170753
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models
BMC Cancer, 10, 433
DOI 10.1186/1471-2407-10-433, PubMed 20716336